IP Library Granted Patent US 12,098,352
Granted Patent B2
US 12,098,352 · App. 16/983,850 · Granted Sep 24, 2024

Stem cell-based lung-on-chip models

Inventors: Janna Nawroth (Boston, MA); Riccardo Barrile (Boston, MA); David Conegliano (Boston, MA); Remi Villenave (Boston, MA); Carolina Lucchesi (Westwood, MA); Justin Nguyen (Medford, MA); Antonio Varone (West Roxbury, MA); Catherine Karalis (Brookline, MA); Geraldine Hamilton (Boston, MA)
Assignee: EMULATE, INC.
C12M23/16B01L3/5027C12N5/0688C12N5/0696C12N2501/115C12N2501/117C12N2501/119C12N2501/155C12N2501/41C12N2502/1323C12N2502/27C12N2503/04C12N2506/02C12N2513/00G01N2800/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,098,352
App. No.
16/983,850
Granted
Sep 24, 2024
Kind
B2
Abstract

An in vitro microfluidic “organ-on-chip” device is described herein that mimics the structure and at least one function of specific areas of the epithelial system in vivo. In particular, a stem cell-based Lung-on-Chip is described. This in vitro microfluidic system can be used for modeling differentiation of cells on-chip into lung cells, e.g., a lung (Lung-On-Chip), bronchial (Airway-On-Chip; small-Airway-On-Chip), alveolar sac (Alveolar-On-Chip), etc., for use in modeling disease states of derived tissue, i.e. as healthy, pre-disease and diseased tissues. Additionally, stem cells under differentiation protocols for deriving (producing) differentiated lung cells off-chips may be seeded onto microfluidic devices at any desired point during the in vitro differentiation pathway for further differentiation on-chip or placed on-chip before, during or after terminal differentiation.

Claims (26)

1. A method, comprising: a) providing a microfluidic device comprising functional Type II lung parenchyma cells and a stroma area or layer comprising fibroblast cells; and b) culturing said functional Type II lung parenchyma cells and said fibroblast cells such that said functional Type II lung parenchyma cells secrete surfactant C in amounts between 30-100 ng/ml, wherein said amounts are secreted daily from day 9 to day 15 of culture.

2. The method of claim 1 , further comprising the step of c) detecting said surfactant C at the protein level.

3. The method of claim 2 , wherein said detecting is by antibody staining.

4. The method of claim 1 , wherein said microfluidic device comprises a surface of a microfluidic channel, said microfluidic channel in fluid communication with a source of fluid.

5. The method of claim 1 , wherein said functional Type II lung parenchyma cells are exposed to an air-liquid interface.

6. The method of claim 1 , wherein said microfluidic device comprises a surface of a chamber, said chamber comprising said stroma area or layer.

7. The method of claim 6 , wherein said stroma area or layer is located adjacent to a spiral channel, wherein said stroma area or layer is separated from the spiral channel by a stretchable membrane.

8. The method of claim 7 , wherein said spiral channel comprises a confluent layer of endothelial cells.

9. A method, comprising: a) providing a microfluidic device comprising functional Type II lung parenchyma cells and a stroma area or layer, wherein each of said stroma area or layer comprises fibroblast cells; and b) culturing said functional Type II lung parenchyma cells and said fibroblast cells such that said functional Type II lung parenchyma cells secrete surfactant C in amounts between 30-100 ng/ml, wherein said surfactant C is secreted in an amounts greater than where said functional Type II lung parenchyma cells are cultured in the absence of said fibroblast cells, wherein said amounts are secreted daily from day 9 to day 15 of culture after introducing said functional Type II lung parenchyma cells into said microfluidic device.

10. The method of claim 9 , further comprising the step of c) detecting said surfactant C at the protein level.

11. The method of claim 10 , wherein said detecting is by antibody staining.

12. The method of claim 9 , wherein said microfluidic device comprises a surface of a microfluidic channel, said microfluidic channel in fluid communication with a source of fluid.

13. The method of claim 9 , wherein said functional Type II lung parenchyma cells are exposed to an air-liquid interface.

14. The method of claim 9 , wherein said microfluidic device comprises a surface of a chamber, said chamber comprising said stroma area or layer.

15. The method of claim 9 , wherein said microfluidic device comprises a stretchable membrane.

16. The method of claim 15 , wherein said stroma area or layer is located adjacent to a spiral channel, wherein said stroma area or layer is separated from the spiral channel by said stretchable membrane.

17. The method of claim 16 , wherein said spiral channel comprises a confluent layer of endothelial cells.

18. The method of claim 16 , further comprising stretching said membrane.

19. A method, comprising:

a) providing: i) a microfluidic device comprising a surface and ii) a population of living cells, wherein at least a portion of said living cells have the capability to differentiate into functional Type II lung parenchyma cells;

b) introducing said living cells into said microfluidic device such that said living cells are positioned on said surface of said microfluidic device so as to create positioned cells; and

c) exposing said positioned cells to conditions that cause at least a portion of said positioned cells to differentiate into functional Type II lung parenchyma cells secreting surfactant C in amounts between 30-100 ng/ml, wherein said amounts are secreted daily from day 9 to day 15 of culture after introducing said living cells into said microfluidic device.

20. The method of claim 19 , further comprising the step of d) detecting said surfactant C at the protein level.

21. The method of claim 20 , wherein said detecting is by antibody staining.

22. The method of claim 19 , wherein said surface of said microfluidic device comprises a surface of a microfluidic channel, said microfluidic channel in fluid communication with a source of fluid.

23. The method of claim 19 , wherein in step c) said positioned cells are exposed to an air-liquid interface.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2025
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: EMULATE, INC.
Reel/Frame 073365/0249 →
RELEASE OF SECURITY INTEREST Recorded Oct 20, 2025
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: EMULATE, INC.
Reel/Frame 073116/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: NAWROTH, JANNA; BARRILE, RICCARDO; CONEGLIANO, DAVID; VILLENAVE, REMI; LUCCHESI, CAROLINA; NGUYEN, JUSTIN; VARONE, ANTONIO; KARALIS, CATHERINE; HAMILTON, GERALDINE
To: EMULATE, INC.
Reel/Frame 068508/0156 →
SECURITY AGREEMENT Recorded Aug 25, 2021
From: EMULATE, INC.
To: PERCEPTIVE CREDIT HOLDINGS III, LP
Reel/Frame 057311/0564 →
Continuity (3)
Continuation PCTUS2019016680 · Feb 5, 2019
Provisional Application 62626427 · Feb 5, 2018
Related Publication 20210062129A1 · Mar 4, 2021